Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000674639 | SCV000800009 | likely pathogenic | Multiple epiphyseal dysplasia type 4 | 2018-05-17 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001855612 | SCV002236491 | pathogenic | Achondrogenesis, type IB; Atelosteogenesis type II; Multiple epiphyseal dysplasia type 4; Diastrophic dysplasia | 2021-10-16 | criteria provided, single submitter | clinical testing | This variant disrupts a region of the SLC26A2 protein in which other variant(s) (p.Ala715Val) have been determined to be pathogenic (PMID: 11448940, 15294877, 21077204). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. This sequence change creates a premature translational stop signal (p.Leu644Trpfs*6) in the SLC26A2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 96 amino acid(s) of the SLC26A2 protein. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with SLC26A2-related conditions. ClinVar contains an entry for this variant (Variation ID: 558379). For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV003472173 | SCV004201757 | likely pathogenic | Achondrogenesis, type IB | 2024-02-24 | criteria provided, single submitter | clinical testing |